The significance of genetic factors in the etiology of schizophrenia: Results from the national study of adoptees in Denmark

doi:10.1016/0022-3956(87)90089-6

Journal of Psychiatric Research

Volume 21, Issue 4, 1987, Pages 423-429

https://doi.org/10.1016/0022-3956(87)90089-6 Get rights and content

Abstract

The prevalence of schizophrenic illness in the biological and adoptive relatives of schizophrenic adoptees has been examined for a total sample of adoptees in Denmark. The total sample was studied in two stages, beginning with the Copenhagen sample of adoptions granted by the courts in the city and county of Copenhagen, the results of which have been reported previously. The adoptions granted by the courts in the remainder of Denmark comprised the Provincial sample the preliminary results of which appear to confirm those obtained earlier. Chronic schizophrenia and milder syndromes described as latent, borderline, or uncertain schizophrenia were found in both samples to concentrate significantly in the biological relatives of schizophrenic adoptees as compared to their controls, but not in their adoptive relatives. These milder and marginal syndromes resembling schizophrenia occurring in the families of schizophrenic patients confirm the observations of Bleuler and others who succeeded him. Their presence in the biological families of schizophrenic adoptees indicates not only their familial but also genetic relationship to schizophrenia.

References (12)

S.S. Kety et al.
The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics
P.H. Wender et al.
A psychiatric assessment of the adoptive parents of schizophrenics
B. Jacobsen et al.
Perinatal complications in adopted and non-adopted schizophrenics and their controls: preliminary results
Acta psychiat. scand. (Suppl)
(1980)
K.S. Kendler et al.
An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia, II: the relationship between schizotypal personality disorder and schizophrenia
Archs gen. Psychiat.
(1981)
K.S. Kendler et al.
An independent analysis of the Danish Adoption Study of schizophrenia VI. The relationship between psychiatric disorders as defined by DSN-III in thhe relatives and adoptees
Archs gen. Psychiat.
(1984)
S.S. Kety
Biochemical theories of schizophrenia. Part 2
Science
(1959)

There are more references available in the full text version of this article.

Cited by (61)

Molecular mechanisms underlying cannabis-induced risk of psychosis
2022, Cannabis and the Developing Brain
Cannabis consumption in early adolescence, a period of increased vulnerability to its effects, increases the risk of developing schizophrenia in vulnerable subjects. Moreover, both cannabis extracts and Δ⁹-tetrahydrocannabinol (THC) can evoke transient psychotic states in healthy subjects and worsen symptoms in schizophrenia patients. However, the neuronal mechanisms underlying vulnerability to develop schizophrenia after cannabis abuse during adolescence remain partially unknown. Nevertheless, several findings suggest that serotonin 2A receptors (5-HT2AR) are involved in the molecular mechanisms underlying psychotic symptoms. In this context, it has been recently demonstrated that chronic administration of THC increases the pro-hallucinogenic signaling of 5-HT2AR in brain cortex of young mice. Moreover, the Akt/mTOR/S6 pathway could mediate the THC effects to turn the signaling of 5-HT2AR from the canonical non-hallucinogenic Gαq/11-proteins activation to the hallucinogenic Gαi/o-protein-dependent response.
Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137
2012, Schizophrenia Research
Citation Excerpt :
Both SZ and BP disorders are debilitating psychiatric illnesses that pose a major burden on public health due to early onset and for many patients, the need for long-term care. While the etiology of these disorders is still unknown, in conjunction with environmental and developmental factors (Kendler et al., 1985; Kety, 1987; Jablensky et al., 1992a, 1992b; Kendler and Diehl, 1993a, 1993b; Kendler et al., 1994a, 1994b; Kendler KS, 1996; Hansen et al., 2007b) there is consistent evidence for a substantial genetic component (Sullivan et al., 2003; Kato et al., 2005) (heritability ~ 80%) with some shared between both diseases (Berrettini, 2003; Purcell et al., 2009a). GWAS are a powerful, systematic and unbiased genetic approach to study the common disease/common variant (CDCV) hypothesis of complex disorders like schizophrenia.
MicroRNAs (miRNAs) are small non-coding RNAs that mainly function as negative regulators of gene expression (Lai, 2002) and have been shown to be involved in schizophrenia etiology through genetic and expression studies (Burmistrova et al., 2007, Hansen et al., 2007a, Perkins et al., 2007, Beveridge et al., 2010, Kim et al., 2010). In a mega analysis of genome-wide association study (GWAS) of schizophrenia (SZ) and bipolar disorders (BP), a polymorphism (rs1625579) located in the primary transcript of a miRNA gene, hsa-miR-137, was reported to be strongly associated with SZ. Four SZ loci (CACNA1C, TCF4, CSMD1, C10orf26) achieving genome-wide significance in the same study were predicted and later experimentally validated (Kwon et al., 2011) as hsa-miR-137 targets.
Here, using in silico, cellular and luciferase based approaches we also provide evidence that another well replicated candidate schizophrenia gene, ZNF804A, is also target for hsa-miR-137.
Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort
2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
Schizophrenia is a chronic psychiatric disorder that is characterised by positive and negative symptoms as well as cognitive disturbances (Van Os and Kapur, 2009). The disorder displays a high heritability (Kety, 1987), yet a comprehensive understanding of the genomic architecture of schizophrenia remains to be elucidated. Complex interactions of numerous genetic variants, combined with the effects of environmental risk factors, as well as phenotypic heterogeneity, are believed to be responsible for this knowledge gap.
The catechol-O-methyltransferase (COMT) gene is an attractive schizophrenia candidate gene, encoding a catabolic dopamine enzyme. The enzyme exists as two distinct isoforms, with the membrane bound enzyme (i.e. MB-COMT) being predominantly expressed in the brain. Since African populations remain underrepresented in genetic/genomic research, we performed an association study to determine whether MB-COMT genetic variants are associated with schizophrenia-susceptibility and symptom severity in the South African Xhosa population.
Fourteen candidate polymorphisms were selected by means of a literature search and in silico analyses and were subsequently genotyped in a cohort of 238 Xhosa schizophrenia patients and 240 healthy Xhosa controls. Genetic association was tested with schizophrenia-susceptibility as well as symptom severity within the patient group. Polymorphisms of interest were also analysed using functional assays.
Two SNPs, rs2020917 (OR = 0.54, 95% CI 0.37–0.79; P = 0.0011) and rs737865 (OR = 0.52, 95% CI 0.36–0.74; P = 0.0002), in the P2 promoter region were significantly associated with schizophrenia as well as an increase (increase = 11.2%, 95% CI 3.7%–19.2%; P = 0.0031) in reporter gene expression. The minor alleles of these SNPs were underrepresented in the schizophrenia cohort, indicating a possible protective effect. The P2 region also formed part of a haplotype found to be associated with the severity of the negative symptoms of the disorder.
The data generated by this study indicate that genetic variation of MB-COMT could be associated with schizophrenia and negative symptom severity in the Xhosa population and may therefore be one of the genomic loci contributing towards the disorder in the South African community. Future large-scale studies in other African schizophrenia populations are required to further elucidate the significance of these findings.
The International Study on General Practitioners and Early Psychosis (IGPS)
2009, Schizophrenia Research
In much of the world, general practitioners (GPs) are the health professionals most frequently initially contacted when a young person is developing psychosis. However little is known about their expertise in assessing psychosis and its risk.
To assess the diagnostic patterns and treatment practices related to psychosis of GPs working in a range of health care systems, questionnaires were mailed to 12,516 randomly selected GPs in seven countries: Canada, Australia, New Zealand, England, Norway, Austria and the Czech Republic. Sites were defined as gatekeeping or non-gatekeeping, based on the primary care health system in effect at each site. A gatekeeping system (GK) is one which mandates that patients see a GP before in order to be referred to a specialist. By contrast, in a non-gatekeeping (nGK) system, individuals can seek help directly from specialists without authorization by a GP.
Twenty-two percent (n = 2784) GPs responded to the mailed questionnaire. They reported low prevalence of early psychosis seen in general practice. Using awareness of functional decline as a prognostic sign as a proxy, gatekeeping (GK) GPs were found to be superior in their knowledge of the signs and symptoms of early psychosis than were non-gatekeeping GPs. GP's with less knowledge as to early psychosis were more likely to refer individuals with suspected psychosis to specialists. GP's reported a preference for access to specialized outpatient services as compared with obtaining continuous medical education relevant to early psychosis. The duration of maintenance treatment recommended by GP's was less than that recommended in international guidelines. GP's also underestimated the risk for relapse after a first episode of psychosis.
As GPs were largely unaware of features of early psychosis, such as functional decline, this should be the target of educational programs for GP's. However, the incidence of psychosis is low and GP's express a preference for access to appropriate referral over continuing medical education. Therefore, the development of specializ ed services for the assessment and care of patients who are in the early stages of developing schizophrenia may be warranted.
Gene expression microarray studies in polygenic psychiatric disorders: Applications and data analysis
2005, Brain Research Reviews
Gene expression microarrays have become a mainstream technology that can provide valuable insight into psychiatric disorders. Gene expression studies in post mortem brain samples of schizophrenia and bipolar disorder have the potential to yield novel clues about the pathophysiology of these complex trait disorders. In the present review, a short introduction of the genetic and molecular background of schizophrenia and bipolar disorder is followed by a discussion of the basic concept and limits of gene expression microarray technology, and the complexities surrounding the analysis of thousands of gene transcripts. Although this review is intended for use in most platforms, it has a particular focus on the commercially available Affymetrix system. Various computer programs and their principal features are discussed, and it is shown how these programs can be applied to reveal a biological context of microarray findings. I will demonstrate how the programs can help to judge the results rather than focus on their statistical principles. The strength of gene array experiments is their emphasis on broad, biological themes, rather than on specific genes, and proper biostatistical approaches are important to ensure reproducibility of the findings. All results should be verified by independent means. This review is intended to help brain researchers who want to apply gene expression microarray technology to conceptualize research strategies and sample analysis.
Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients
2022, European Psychiatry

View all citing articles on Scopus

^☆: Presented at the Symposium of Genetic Research in Psychiatry, Berlin, 27 September 1986.

View full text

The significance of genetic factors in the etiology of schizophrenia: Results from the national study of adoptees in Denmark☆

Abstract

Perinatal complications in adopted and non-adopted schizophrenics and their controls: preliminary results

Acta psychiat. scand. (Suppl)

An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia, II: the relationship between schizotypal personality disorder and schizophrenia

Archs gen. Psychiat.

An independent analysis of the Danish Adoption Study of schizophrenia VI. The relationship between psychiatric disorders as defined by DSN-III in thhe relatives and adoptees

Archs gen. Psychiat.

Biochemical theories of schizophrenia. Part 2

Science